Exact Sciences Corporation (EXAS): Price and Financial Metrics


Exact Sciences Corporation (EXAS)

Today's Latest Price: $106.11 USD

6.50 (6.53%)

Updated Oct 22 1:33pm

Add EXAS to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 58 in Medical - Diagnostics/Research

See all "A" rated Strong Buy stocks

EXAS Stock Summary

  • EXAS has a market capitalization of $14,958,166,745 -- more than approximately 88.4% of US stocks.
  • EXAS's price/sales ratio is 13.22; that's higher than the P/S ratio of 89.14% of US stocks.
  • As for revenue growth, note that EXAS's revenue has grown 81.5% over the past 12 months; that beats the revenue growth of 93.54% of US companies in our set.
  • Stocks that are quantitatively similar to EXAS, based on their financial statements, market capitalization, and price volatility, are HZNP, AYX, BL, NTRA, and IRTC.
  • EXAS's SEC filings can be seen here. And to visit Exact Sciences Corp's official web site, go to www.exactsciences.com.

EXAS Stock Price Chart Interactive Chart >

Price chart for EXAS

EXAS Price/Volume Stats

Current price $106.11 52-week high $110.74
Prev. close $99.61 52-week low $35.25
Day low $100.00 Volume 785,896
Day high $106.39 Avg. volume 1,949,579
50-day MA $88.61 Dividend yield N/A
200-day MA $83.93 Market Cap 15.93B

Exact Sciences Corporation (EXAS) Company Bio


Exact Sciences is a molecular diagnostics company focused on gastrointestinal cancers. The company develops the Cologuard, a non-invasive stool-based DNA colorectal cancer screening test that is designed to detect pre-cancerous lesions or polyps, and each of the four stages of colorectal cancer. The company was founded in 1995 and is based in Madison, Wisconsin.


EXAS Latest News Stream


Event/Time News Detail
Loading, please wait...

EXAS Latest Social Stream


Loading social stream, please wait...

View Full EXAS Social Stream

Latest EXAS News From Around the Web

Below are the latest news stories about Exact Sciences Corp that investors may wish to consider to help them evaluate EXAS as an investment opportunity.

Marinus Epilepsy Study, And Other News: The Good, Bad And Ugly Of Biopharma

Marinus Pharmaceuticals provides updates for pivotal epilepsy study Marinus Pharmaceuticals Inc. (MRNS) reported that it has met the conditions with regard to its protocol raised by the FDA. The protocol-related questions were in relation to the registrational Phase 3 trial for refractory status epilepticus. The company is now ready to...

Avisol Capital Partners on Seeking Alpha | September 28, 2020

Genetron: 3 Reasons To Stay Bullish On China's Early-Stage Cancer Screening

GRAIL (GRAL) recently announced its intention to apply for an IPO on September 9th, US time. If the IPO goes smoothly, GRAIL will be the third Nasdaq-listed biotech company based on Next-Generation Sequencing ((NGS)) technology in the early-stage cancer detection area. Earlier in June, two Chinese companies, Burning Rock Biotech...

EqualOcean on Seeking Alpha | September 25, 2020

Why Exact Sciences Stock Is Trading Higher Today

Exact Sciences (NASDAQ: EXAS) shares are trading higher on Thursday after the company’s CEO Kevin Conroy presenting at Cowen's Liquid Biopsy …

Benzinga | September 24, 2020

Exact Sciences to participate in Cowen Liquid Biopsy Summit

MADISON, Wis., Sept. 17, 2020 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will participate in the following event and invited investors to participate by webcast. Cowen Liquid Biopsy Summit Presentation on Thursday, September 24, 2020, at…

PR Newswire | September 17, 2020

Exact Sciences to participate in September investor conference

MADISON, Wis., Sept. 1, 2020 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will participate in the following conference and invited investors to participate by webcast. Baird Global Healthcare Conference Fireside Chat on Wednesday, September…

PR Newswire | September 1, 2020

Read More 'EXAS' Stories Here

EXAS Price Returns

1-mo 45.52%
3-mo 11.24%
6-mo 40.62%
1-year 21.27%
3-year 116.64%
5-year 1,239.77%
YTD 14.74%
2019 46.56%
2018 20.10%
2017 293.26%
2016 44.75%
2015 -66.36%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7504 seconds.